Derby L E, Jick H
Boston Collaborative Drug Surveillance Program, Boston University Medical Center, Lexington, MA, USA.
Epidemiology. 1996 Jul;7(4):358-62. doi: 10.1097/00001648-199607000-00004.
Acetaminophen is a metabolite of phenacetin, a drug that has been implicated as a causal agent in the development of renal and bladder cancer. We conducted matched case-control studies to estimate the risk of renal and bladder cancer among heavy users of acetaminophen, using data from Group Health Cooperative of Puget Sound. For the renal cancer study, we identified 222 incident cases diagnosed in the years 1980-1991 and 885 controls. For bladder cancer, we identified 504 cases and 2,009 controls. Exposure was defined according to the number of prescriptions for acetaminophen and acetaminophen-containing drugs filled at the Group Health Cooperative pharmacy. The relative risk estimate for renal cancer for subjects who filled 40 or more prescriptions was 2.6 [95% confidence limits (CL) = 1.1, 6.0], compared with the risk for subjects who did not fill any prescriptions for acetaminophen. We found only a small increased risk of bladder cancer among subjects with heavy acetaminophen exposure (odds ratio = 1.3; 95% CL = 0.6, 2.8).
对乙酰氨基酚是非那西丁的一种代谢产物，非那西丁被认为是导致肾癌和膀胱癌的一种致病因素。我们利用普吉特海湾卫生保健合作组织的数据，开展了配对病例对照研究，以评估对乙酰氨基酚大量使用者患肾癌和膀胱癌的风险。在肾癌研究中，我们确定了1980年至1991年间确诊的222例新发病例和885名对照。在膀胱癌研究中，我们确定了504例病例和2009名对照。暴露情况根据在卫生保健合作组织药房开具的对乙酰氨基酚及含对乙酰氨基酚药物的处方数量来定义。与未开具任何对乙酰氨基酚处方的受试者相比，开具40张或更多处方的受试者患肾癌的相对风险估计值为2.6 [95%置信区间(CL) = 1.1, 6.0]。我们发现，对乙酰氨基酚大量暴露的受试者患膀胱癌的风险仅略有增加(比值比 = 1.3; 95% CL = 0.6, 2.8)。
